info@salutesicilia.com

IRF5 as a specific target in systemic lupus: the innovational drug discovery is on the way

IRF5 as a specific target in systemic lupus: the innovational drug discovery is on the way

Medicomunicare Magazine | Health and Medical News

Systemic lupus erythematosus (SLE) is an chronic autoimmune disease characterized by a breakdown of immune tolerance to nuclear self-antigens. Current standard therapies for SLE include steroids, immunosuppressants, DMARDs and biologics among which the most recently approved is a monoclonal antibody against the cytokine BAFF. Owing to these therapies, the 10-year survival rate has improved from

Read More